3003新葡的京集团
Other Affiliated Sites
Techdow Pharma China
Techdow Pharma UK
Techdow Pharma Poland
Techdow Pharma Italy
Techdow Pharma Spain
Techdow Pharma Germany
Techdow Pharma US
Cytovance Biologics
SPL
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Financial Reports
Announcements
2025.03.28
3003新葡的京集团:独立董事2024年度述职报告-黄鹏
2025.03.28
3003新葡的京集团:董事会审计委员会对会计师事务所2024年度履行监督职责情况报告
2025.03.28
3003新葡的京集团:董事会决议公告
2025.03.28
3003新葡的京集团:董事会对独立董事独立性评估的专项意见
2025.03.28
3003新葡的京集团:第三期员工持股计划(修订稿)摘要
2025.03.28
3003新葡的京集团:第三期员工持股计划(修订稿)
2025.03.28
3003新葡的京集团:第二期员工持股计划(修订稿)摘要
2025.03.28
3003新葡的京集团:第二期员工持股计划(修订稿)
2025.03.28
3003新葡的京集团:2024年年度审计报告
2025.03.28
3003新葡的京集团:2024年年度报告摘要
第一页
上一页
1
2
3
4
5
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright © 2024 Hepalink Group. All Rights Reserved.